TweetOn August 20, 2013, Novartis announced in a press release that the FDA had granted breakthrough therapy designation to its experimental agent BYM338 (bimagrumab) for treatment of the rare muscle wasting disease sporadic inclusion body myositis (sIBM). sIBM is a rare–but increasingly prevalent–disease. It is the most common cause of inflammatory myopathy in people over…